User menu

Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models: A Conceptual Framework

Bibliographic reference Dahl, Svein G. ; Aarons, Leon ; Gundert-Remy, Ursula ; Karlsson, Mats O. ; Schneider, Yves-Jacques ; et. al. Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models: A Conceptual Framework. In: Basic & Clinical Pharmacology & Toxicology, Vol. 106, no. 1, p. 2-12 (2010)
Permanent URL http://hdl.handle.net/2078.1/34297
  1. Sheiner, Annu Rev Pharmacol Toxicol, 40, 67 (2000)
  2. Biomarkers-Definitions-Working-Group, Clinical Pharmacol Ther, 69, 89 (2001)
  3. Hopkins, Nat Rev Drug Discov, 1, 727 (2002)
  4. Dahl, J Pharmacol Exp Ther, 309, 853 (2004)
  5. Palczewski, Science, 289, 739 (2000)
  6. Dahl, Basic Clin Pharmacol Toxicol, 96, 151 (2005)
  7. Rasmussen, Nature, 450, 383 (2007)
  8. Bonacci, Science, 312, 443 (2006)
  9. Menniti, Nat Rev Drug Discov, 5, 660 (2006)
  10. Barton, Nat Rev Drug Discov, 5, 281 (2006)
  11. Kellendonk, Neuron, 49, 603 (2006)
  12. Barton, Toxicol Sci, 99, 395 (2007)
  13. Bouvier d’Yvoire, Altern Lab Anim, 35, 661 (2007)
  14. Clewell, Regul Toxicol Pharmacol, 50, 129 (2008)
  15. Loizou, Regul Toxicol Pharmacol, 50, 400 (2008)
  16. Levy Gerhard, Kinetics of pharmacologic effects, 10.1002/cpt196673362
  17. Gibaldi, Anesthesiology, 36, 213 (1972)
  18. Nagashima R., O'Reilly R. A., Levy G., Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin, 10.1002/cpt196910122
  19. Åblad, Eur J Clin Pharmacol, 5, 44 (1972)
  20. Dayneka, J Pharmacokinet Biopharm, 21, 457 (1993)
  21. Mager, Drug Metab Dispos, 31, 510 (2003)
  22. Noble, Science, 295, 1678 (2002)
  23. Holford, Clin Pharmacokinet, 6, 429 (1981)
  24. Mandona Jaap W, Tuk Bert, van Steveninck Alfred L, Breimer Douwe D, Cohen Adam F, Danhof Meindert, Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers, 10.1038/clpt.1992.84
  25. Hempel, Clin Pharmacol Ther, 64, 622 (1998)
  26. Nagaraja, Clin Pharmacol Ther, 68, 617 (2000)
  27. Sallstrom, J Pharmacokinet Pharmacodyn, 32, 835 (2005)
  28. Chan, Annu Rev Pharmacol Toxicol, 41, 625 (2001)
  29. Holford, Principles of Clinical Pharmacology, 253 (2001)
  30. Schuttler, J Pharmacokinet Biopharm, 15, 241 (1987)
  31. Mandema, J Pharmacol Exp Ther, 260, 36 (1992)
  32. Pedraz, J Pharm Sci, 81, 232 (1992)
  33. Sheiner Lewis B., Stanski Donald R., Vozeh Samuel, Miller Ronald D., Ham Jay, Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application tod-tubocurarine, 10.1002/cpt1979253358
  34. Troc??niz I??aki F, Wolters Jan-Markus, Tillmann Christiane, Schaefer Hans G, Roth Willy, Modelling the Anti-Migraine Effects of BIBN 4096 BS : A New Calcitonin Gene-Related Peptide Receptor Antagonist, 10.2165/00003088-200645070-00006
  35. Sharma, Br J Clin Pharmacol, 45, 229 (1998)
  36. Porchet, J Pharmacol Exp Ther, 244, 231 (1988)
  37. Movin-Osswald, J Pharmacol Exp Ther, 274, 921 (1995)
  38. Fattinger, J Pharmacol Exp Ther, 281, 1238 (1997)
  39. Gardmark, Clin Pharmacokinet, 36, 145 (1999)
  40. Francheteau, Simulation for Designing of Clinical Trials, 327 (2002)
  41. Francheteau, J Pharmacokinet Biopharm, 21, 489 (1993)
  42. Friberg, J Clin Oncol, 20, 4713 (2002)
  43. Hayashi, Br J Clin Pharmacol, 63, 548 (2007)
  44. Lammerts van Bueren, Cancer Res, 66, 7630 (2006)
  45. Uehlinger Dominik E, Gotch Frank A, Sheiner Lewis B, A pharmacodynamic model of erythropoietin therapy for uremic anemia, 10.1038/clpt.1992.10
  46. Jauslin, J Clin Pharmacol, 47, 1244 (2007)
  47. Silber, J Clin Pharmacol, 47, 1159 (2007)
  48. de Winter, J Pharmacokinet Pharmacodyn, 33, 313 (2006)
  49. Zuideveld, Am J Physiol Regul Integr Comp Physiol, 281, R2059 (2001)